PHARMACO-KINESIS CORPORATION COMPLETES $5 MILLIION ROUND B FINANCING

INGLEWOOD, CALIFORNIA, September 20, 2011– Ric Gallaher, Senior Vice President of Pharmaco-Kinesis Corporation (PKC), a medical device company developing smart local drug delivery systems, today announced the completion on September 19, 2011 of its Series B financing of $5 million in equity capital. Proceeds from the Round B financing were used for the development of PKC’s innovative Metronomic Biofeedback Pump (MBP).  The MBP development program included preparation of the MBP for human trials and use of the pump in large animal studies.  “PKC has met the milestones associated with our Round B financing, and we look forward to the pre-commercialization programs we plan to achieve with the support of our Round C financing,” said Frank Adell, Chief Executive Officer of PKC.  “Our upcoming focus on regulatory work will enable PKC to prove the safety and efficacy of our MBP.  In this process, we believe that the MBP will greatly improve the lives of patients with deadly diseases such as Leptomeningeal Carcinomatosis.”

About the MBP

Current treatments for cancer have relied primarily on combination therapy using surgical removal, systemic chemotherapy, and radiation therapy. The MBP represents a fourth treatment modality by using localized, programmable delivery of drugs based upon the patient's specific physiology. The MBP is the first fully implantable pump specifically designed for local, metronomic delivery of chemotherapeutic agents.  It not only delivers a variety of medications to a treatment location but also obtains sample fluid from the tumor via its multi-lumen catheter, closing the feedback loop in patient-specific treatments.

“Multiple studies have shown that continuous flow of medication, administration of alternate drug regimens or drug combinations, and adaptation of dosage to individualized patient needs can improve survival rates, but as of yet, no device has been developed with these capabilities,” said Dr. Chen.  “The MBP automatically dispenses precise quantities of chemotherapeutics directly to the site of cancer according to delivery regimens prescribed by the physician.  This treatment modality has the potential to considerably improve the quality of life for patients with LC and a range of cancer conditions.”

About PKC

PKC is an early-stage high technology medical device company that aims to optimize the healing of the human body through proprietary local Smart Drug Delivery Systems™ and associated advanced devices to measure biological responses. 

See PKC’s website at: www.pharmaco-kinesis.com